{"filings":[{"id":2198879,"accession_number":"0001193125-26-345732","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-08-12T11:15:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q2 net loss narrows to $30.4M; first patient dosed in Phase 3 ALLOHA-2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $30.4M vs $37.0M; revenue $1.1M vs $3.1M, down on Amgen collaboration timing.","Cash $100.2M at 6/30/26 funds ops into Q2 2027; missed debt milestones trigger term loan amortization from Q4 2026.","First patient dosed in Phase 3 ALLOHA-2 (TSC-101, heme malignancies); topline expected mid-2028.","Cohort C ALLOHA data: 79% (11/14) complete donor chimerism ~3 weeks post-TSC-101; ~90% (17/19) first-pass manufacturing success.","TSC-102-A01 and TSC-102-A03 Phase 1 trials expected Q4 2026; solid-tumor IND roadmap by H2 2027 after FDA INTERACT engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1176879,"accession_number":"0001193125-26-276693","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-06-22T11:09:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.","~90% manufacturing success rate (17/19) with commercial-ready process; 14/19 patients received first infusion.","One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT.","TSC-101 well-tolerated; safety consistent with Cohort A; company plans to initiate Phase 3 ALLOHA-2 study this month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609400,"accession_number":"0001193125-26-236862","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-05-22T20:05:44+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"TScan Therapeutics stockholders approve doubling authorized shares to 600M and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Katina Dorton (19.7M for) and R. Keith Woods (23.3M for) elected as Class II directors for three-year terms.","Deloitte & Touche ratified as independent auditor for fiscal year ending Dec 31, 2026 (38.5M for).","Amendment to increase authorized voting common stock from 300M to 600M shares approved (35.9M for).","Proposal to adjourn meeting not needed; quorum and sufficient proxies already present.","Annual meeting held on May 20, 2026; no other matters submitted to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95407,"accession_number":"0001193125-26-207549","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q1 2026 revenue $1.0M, net loss $28.7M, cash funds into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.0M vs $2.2M Q1 2025; net loss $28.7M vs $34.1M; R&D expenses $21.9M down from $29.8M.","Cash and equivalents $128.1M plus $5M restricted cash, funding operations into second half of 2027.","Phase 3 study of TSC-101 planned to start Q2 2026; early Cohort C data expected Q2 2026.","Phase 1 trial of TSC-102-A01/A03 targeting CD45 to initiate in second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":982000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95406,"accession_number":"0001193125-26-138973","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TScan Therapeutics VP of Finance resigns; CFO Amello named principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leiden Dworak resigns as VP of Finance and principal accounting officer, effective April 10, 2026.","No disagreements between Dworak and TScan regarding operations, policies, or practices.","CFO Jason A. Amello appointed as principal accounting officer, effective same date.","Amello receives no additional compensation for assuming the principal accounting officer role.","Amello's background is incorporated by reference from TScan's May 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108467,"accession_number":"0001193125-26-089871","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Therapeutics Q4 net loss $23M; cash $152.4M; FDA clears TSC-102 INDs; plans Phase 3 trial Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.0M in Q4 2025 vs $35.8M Q4 2024; revenue $2.6M vs $0.7M.","Cash and equivalents $152.4M as of Dec 31, 2025; funds operations into H2 2027.","FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 for heme malignancies post-HCT.","Enrollment completed in Cohort C of ALLOHA heme trial with commercial-ready manufacturing; initial data due Q2 2026.","Discontinued solid tumor PLEXI-T trial; advancing in vivo TCR-T engineering and autoimmunity programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108466,"accession_number":"0001193125-26-009771","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TScan furnishes corporate presentation at J.P. Morgan conference; no specific new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished corporate presentation in connection with 44th Annual J.P. Morgan Healthcare Conference.","Presentation intended for meetings with investors and analysts during the week of January 12, 2026.","No financial or clinical updates provided in the filing; presentation content not observable from exhibits.","Filing under Item 7.01 Regulation FD; presentation available on company's IR website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124903,"accession_number":"0001193125-25-300538","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TScan Therapeutics retention program grants cash and RSUs to CEO, CFO, CMO tied to TSC-101 milestone","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board approved retention program for CEO Gavin MacBeath, CFO Jason Amello, and CMO Chrystal Louis.","Cash awards: $399K (CEO), $170K (CFO), $250K (CMO); 50% paid upon TSC-101 pivotal trial milestone, 50% on first anniversary.","Equity awards: 1M RSUs (CEO), 270K RSUs (CFO), 650K RSUs (CMO) granted upon milestone; vest 25% at year 2, 75% at trial completion or year 4.","Awards subject to continued employment and terms of 2021 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124902,"accession_number":"0001193125-25-275889","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.","FDA agreed on pivotal trial design for TSC-101 in AML/MDS; pivotal launch expected Q2 2026.","Strategic decision: prioritize heme program, pause PLEXI-T solid tumor enrollment; shift to in vivo engineering.","Plans to present updated ALLOHA heme data at ASH Dec 2025; two IND submissions for heme candidates in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":7758000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124901,"accession_number":"0001193125-25-261612","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"TScan Therapeutics restructures, cuts 30% of workforce, pauses solid tumor trial, extends cash runway to H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.","Workforce reduced by ~30% (66 roles); expects $2.3M severance charge in Q4 2025.","Strategic prioritization yields ~$45M annual cost savings in 2026-27; cash runway extended to H2 2027.","Pauses further enrollment in solid tumor Phase 1 PLEXI-T trial; to present initial data Q1 2026.","First two patients dosed with multiplex TCR-T in solid tumors; shifting preclinical focus to in vivo engineering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141616,"accession_number":"0001193125-25-198768","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TScan Therapeutics updates corporate presentation with adjusted timelines and pipeline updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished updated corporate presentation on September 9, 2025 for investor meetings.","Presentation includes adjusted timelines for solid tumor program and pipeline updates across hematologic malignancies and solid tumors.","Updates on target discovery initiatives in autoimmunity also included; specific numerical details not disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141615,"accession_number":"0001193125-25-184083","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TScan Therapeutics appoints Leiden Dworak as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective August 14, 2025; Dworak also serves as VP Finance since April 2022.","Jason Amello ceases as Principal Accounting Officer but remains CFO and Principal Financial Officer.","Dworak previously held the same PAO role from July 2023 to January 2024.","17 years biotech finance experience including VP Finance at AVROBIO and Director at Moderna."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141614,"accession_number":"0000950170-25-106915","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q2 net loss $37M, cash ~$218M funds ops into Q1 2027; heme/solid tumor milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $3.1M (vs $0.5M YoY) from Amgen collaboration; R&D spend $32.6M.","Net loss $37M vs $31.7M in Q2 2024; cash+equivalents+securities $218M (excl. $5M restricted).","Expects to dose first solid tumor patients with multiplex TCR-T in Q3 2025; initial safety/response data in Q1 2026.","Plans to initiate registrational trial for TSC-101 in H2 2025 and file IND for TSC-102-A0301 in H2 2025.","ALL OHA Phase 1 two-year relapse data on TSC-101 to be presented by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":5247000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141613,"accession_number":"0001193125-25-154336","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TScan Therapeutics holds annual meeting; elects three Class I directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Stephen Biggar, Gavin MacBeath, and Garry Nicholson as Class I directors for three-year terms through 2028.","Garry Nicholson received 25.65M votes for and 5.86M withheld; Biggar and MacBeath each received >31M votes for.","Ratified Deloitte & Touche as independent auditor for FY2025 with 45.72M votes for, 64K against, 36K abstain.","Broker non-votes totaled 14.31M on director elections, indicating some institutional abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159486,"accession_number":"0000950170-25-063959","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.","Cash, equivalents, and marketable securities $251.7M (plus $5.0M restricted) funding operations into Q1 2027.","On track to initiate registrational trial for TSC-101 and file IND for TSC-102-A0301 in H2 2025.","First patient dosing with multiplex TCR-T therapy expected H1 2025; safety/efficacy data by year-end.","Appointed Stephen Camiolo as SVP Market Access; presenting at ASGCT and Bank of America conference."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2171000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177864,"accession_number":"0000950170-25-033071","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q4 net loss $35.8M; revenue down 90% YoY; heme relapse data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.8M in Q4 vs $19.6M YoY; full-year net loss $127.5M vs $89.2M.","Revenue $0.7M Q4 vs $7.2M YoY; full-year $2.8M vs $21.0M, due to Amgen collaboration timing.","Cash, equivalents and marketable securities $290.1M; funding into Q1 2027.","ASH heme trial: 2/26 (8%) relapsed vs 4/12 (33%) control; HR 0.30.","IND cleared for MAGE-A4 TCR-T; closed $30M registered direct offering at 37% premium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194576,"accession_number":"0001193125-24-284671","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TScan Therapeutics raises $30M via registered direct offering of pre-funded warrants to Lynx1 Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered securities purchase agreement for pre-funded warrants to purchase 7.5M shares at $4.00 per warrant, gross proceeds ~$30M.","Purchaser is Lynx1 Capital Management LP and an affiliated fund, an existing shareholder.","Net proceeds ~$29.8M for general corporate purposes; closing expected Dec 27, 2024.","Cash runway extended into Q1 2027 based on net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194575,"accession_number":"0001193125-24-283673","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"TScan refinances convertible debt with up to $52.5M term loan from Silicon Valley Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First tranche of $32.5M drawn at closing; used to retire $17.2M existing convertible debt with K2 HealthVentures plus $2.1M exit fee.","Second tranche of $20M available through June 30, 2026 at SVB's sole discretion.","Interest rate is greater of 7.00% or prime minus 0.75%, capped at 9.75%; maturity September 1, 2029 with interest-only through Sept 2027 if milestones met.","Company expects cash resources to fund operating plan into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194574,"accession_number":"0001193125-24-273985","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).","2 of 26 (8%) treatment-arm patients relapsed vs 4 of 12 (33%) controls; median time to relapse not evaluable vs 160 days.","No TP53-mutated patients relapsed in treatment arm (0/4 infused), while both control-arm TP53 patients relapsed within 6 months and died.","Registrational trial for TSC-101 planned for H2 2025 with RFS primary endpoint, powered at HR 0.60, 85% power, ~140 treatment subjects.","Solid tumor program: 8 patients infused singleplex; first T-Plex product manufactured; IND for MAGE-A4 TCR submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194573,"accession_number":"0000950142-24-002817","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"TScan converts $15M loan principal into 3.13M shares at $4.785","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["K2 HealthVentures converted $15M of convertible term loan into 3,134,796 voting common shares at $4.785/share.","Shares issued November 20, 2024 under Section 3(a)(9) exemption; no registration statement required.","Conversion reduces debt but dilutes existing stockholders by approximately 5.5% based on shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194572,"accession_number":"0000950170-24-124558","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q3 net loss $29.9M; ALLOHA heme trial shows no relapses in 16 treatment patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.9M in Q3 2024 vs $23.0M in Q3 2023; revenue $1.0M vs $3.9M.","Cash $271.1M, excluding $5M restricted cash; funding operations into Q4 2026.","ALLOHA Phase 1 heme trial: 16/16 treatment-arm patients relapse-free and MRD-negative as of July 8 cutoff; 3/11 control-arm relapses.","On track to dose first patient with multiplex TCR-T therapy and provide Phase 1 update by end of 2024.","IND filing for MAGE-A4-targeted TCR-T (TSC-202-A0201) planned by end of year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":2151000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194571,"accession_number":"0001193125-24-249124","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"TScan Therapeutics expands leased space by ~25,628 sq ft at Waltham HQ through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease amendment adds 25,628 rentable sq ft to existing 25,472 sq ft at 830 Winter St, Waltham, MA.","New term runs from Q4 2024 to Oct 31, 2029; initial monthly base rent $163,378.50.","Rent escalates annually: $168,279.86 (yr 2), $173,328.25 (yr 3), $178,528.10 (yr 4), $183,883.94 (yr 5).","Landlord provides tenant improvement allowance of up to ~$2,681,540."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210894,"accession_number":"0000950170-24-095063","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q2 net loss $31.7M; revenue falls to $0.5M; RMAT designation for lead candidates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.5M, down from $3.1M in Q2 2023, primarily due to Amgen collaboration timing.","Net loss $31.7M vs $24.0M in Q2 2023; R&D expenses increased to $26.9M from $21.2M.","Cash, equivalents, and marketable securities $297.7M (plus $5M restricted); funds into Q4 2026.","FDA granted RMAT designation for TSC-100 and TSC-101 for AML, ALL, MDS post-HCT.","On track to report one-year heme data and initial solid tumor data by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":1102000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229321,"accession_number":"0001193125-24-161151","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"TScan Therapeutics appoints Garry Nicholson to board, Stephen Biggar named chair; Barberich retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Barberich resigned as director and Chair effective June 12, 2024; no disagreement cited.","Stephen Biggar, M.D., Ph.D., assumed Chair role; Nicholson appointed to Board effective same date.","Garry Nicholson brings 35+ years oncology experience, including former President of Pfizer Oncology.","Stockholders approved Amended 2021 Equity Plan adding 2M shares; non-employee directors granted options for 308,750 shares at $8.88.","Nicholson receives initial option for 71,250 shares, vesting over one year or next annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229320,"accession_number":"0000950170-24-058194","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan reports Q1 2024 results: net loss $30.1M, first solid tumor patient dosed, heme patients relapse-free","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.1M for Q1 2024 compared to $22.6M in Q1 2023; revenue fell to $0.6M from $6.8M.","First patient dosed in Phase 1 solid tumor trial with TSC-203-A0201 targeting PRAME; initial data expected H2 2024.","All eight heme treatment-arm patients relapse-free with median follow-up >10 months; two control patients relapsed.","Closed upsized $167.8M public offering in April; cash and marketable securities $162.8M at March 31, extending runway to Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":566000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229319,"accession_number":"0001193125-24-098509","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"TScan Therapeutics prices upsized $150M public offering; provides preliminary cash of $162.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 2,472,581 shares at $7.13/share and pre-funded warrants for 18,577,419 shares at $7.1299/warrant.","Gross proceeds ~$150.1M; net proceeds ~$144.7M (or ~$165.9M if underwriters exercise overallotment for 3,157,500 additional shares).","Cash, cash equivalents and marketable securities of $162.8M as of March 31, 2024 (preliminary, unaudited).","Proceeds expected to fund operations into Q4 2026; use for general corporate purposes.","Offering expected to close April 19, 2024; Morgan Stanley and TD Cowen joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229318,"accession_number":"0001193125-24-097764","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.","Control arm (transplant alone) had 2 relapses at ~6 months and 1 death; only 1 of 8 achieved complete donor chimerism.","Solid tumor: >40 patients screened; ~60% qualify for at least one TCR-T, ~30% eligible for multiplex (T-Plex) therapy.","First 3 solid tumor patients expected to be dosed early May 2024; initial data from singleplex and multiplex cohorts in H2 2024.","Heme: expansion cohorts at Phase 2 dose planned Q3 2024; Phase 1 enrollment completion and 1-year data in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229317,"accession_number":"0001193125-24-089164","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TScan Therapeutics appoints Chrystal U. Louis as CMO; Dr. Debora Barton departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chrystal U. Louis, M.D., M.P.H., named Chief Medical Officer effective April 8, 2024.","Dr. Louis brings 20+ years of hematology/oncology drug development and cell therapy experience.","Outgoing CMO Dr. Debora Barton departing for personal reasons; will continue as consultant.","Dr. Barton joined TScan in July 2022; contributed to heme program and solid tumor initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247896,"accession_number":"0000950170-24-026868","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q4 net loss $19.6M; all 8 TSC-100/101 patients relapse-free","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $7.2M (up from $3.1M YoY); full-year revenue $21.0M. R&D expenses $22.4M Q4, $88.2M full year.","Cash $192M as of Dec 31, 2023; cash runway into 2026.","Phase 1 heme data: 8/8 treatment-arm patients relapse-free; one high-risk MDS patient reached 1 year post-TSC-101.","FDA cleared INDs for TSC-201-B0702 (MAGE-C2) and TSC-204-A0101 (MAGE-A1); solid tumor trial enrolling.","Appointed Jason Amello as CFO, Justin McCue as CTO; promoted several executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247895,"accession_number":"0001193125-24-017379","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TScan Therapeutics appoints Jason A. Amello as CFO effective Jan 29, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason A. Amello appointed CFO effective January 29, 2024; previously CFO at Candel Therapeutics, Akebia, and Saniona.","Base salary of $500,000 per annum, one-time payment of $60,000, option for 750,000 shares vesting over 4 years.","Eligible for discretionary bonus target up to 40% of base salary; severance and change-of-control provisions consistent with non-CEO executives.","Prior interim CFO responsibilities held by CEO Gavin MacBeath and VP Finance Leiden Dworak cease as of Start Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265330,"accession_number":"0001193125-23-292080","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TScan Phase 1 TCR-T data: 6/6 patients achieve complete donor chimerism and MRD negativity; 0/4 controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.","One AML patient MRD-positive post-HCT converted to MRD-negative after TSC-101 treatment.","Control arm: one TP53-mutated MDS patient relapsed at ~6 months; two others had worsening chimerism requiring clinical intervention.","Dose escalation reached third and final level with no dose-limiting toxicities; recommended Phase 2 dose expected from this level.","Company hosting virtual KOL event Dec 11 to discuss data; 10 clinical sites active with expansion cohorts planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265329,"accession_number":"0001193125-23-290309","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TScan Therapeutics appoints R. Keith Woods to Board of Directors, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Woods appointed as Class II director, serving on Audit and Compensation Committees.","Over 30 years life science experience; most recently COO of argenx, leading commercialization.","Received option to purchase 17,500 shares of TCRX common stock, vesting over one year or until 2024 annual meeting.","Board committees: Audit (Woods, Dorton, Gruia, Klencke); Compensation (Woods, Biggar, Dorton, Klencke)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265328,"accession_number":"0000950170-23-061525","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.","Cash, equivalents, and marketable securities $215.4M as of Sept 30; funding operations into 2026.","FDA cleared IND for TSC-203-A0201 targeting PRAME; plans to file two additional INDs by year-end.","Expects initial heme program data at ASH Dec 2023; solid tumor Phase 1 enrollment by year-end 2023.","R&D expenses $22.7M, up $7.7M YoY due to clinical start-up costs and personnel expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":13838000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282541,"accession_number":"0000950170-23-040954","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q2 net loss $24M, cash $208.8M; heme and solid tumor trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M in Q2 2023, vs $15.1M in Q2 2022; revenue $3.1M (down from $4.1M).","Ended Q2 2023 with cash $208.8M; raising $134.7M net from June public offering; funded into 2026.","FDA cleared IND for TSC-200-A0201 (HPV16); third solid tumor IND; three TCR-Ts to enter Phase 1 basket study H2 2023.","Heme malignancies: TSC-100/101 at dose level 2, no DLTs; expect RP2D and interim data by end of 2023.","Plans to file INDs for three more TCR-Ts by year-end, including PRAME-targeting TSC-203-A0201."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":9951000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282540,"accession_number":"0001193125-23-192484","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TScan Therapeutics CFO Brian Silver resigns; CEO MacBeath appointed interim CFO, Dworak as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Silver resigned as CFO, effective July 21, 2023; CEO Gavin MacBeath named interim Principal Financial Officer.","Leiden Dworak appointed Principal Accounting Officer, effective July 21, 2023; previously VP, Finance since April 2022.","Dworak's base salary increased to $340,000; target bonus raised to 35% from 30%; granted 25,000 stock options at $2.23.","Stock options vest over four years (25% one-year cliff, then monthly). No family relationships or related party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301788,"accession_number":"0001193125-23-178075","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TScan CFO Brian Silver to step down effective July 21, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO and Treasurer Brian Silver resigns, effective July 21, 2023, to join an advisory firm in New York.","Silver will continue to provide strategic advice to the company post-departure.","Company has initiated a search for a successor chief financial officer.","Silver noted financial runway into 2026 from convertible note, Amgen partnership, and follow-on financing.","Resignation is not due to any disagreement with TScan's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301787,"accession_number":"0001193125-23-168118","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"TScan shareholders approve 7.5M share increase to 2021 equity plan; options granted to executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Plan Amendment increasing authorized shares by 7,500,000 to 10,778,048 at June 13 annual meeting.","CEO Gavin MacBeath granted options for 1,121,300 shares at $2.49; CFO Brian Silver granted 632,500 shares at $2.49, contingent on amendment approval.","Non-employee director option grants increased to 35,000 shares per director annually, vesting at earlier of one year or next annual meeting.","Board committee changes: Barbara Klencke joins Audit and Compensation; Gabriela Gruia joins Audit and Nominating; Timothy Barberich steps down from all committees.","Stockholders also elected Katina Dorton as Class II director and ratified Deloitte & Touche as independent auditor for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301786,"accession_number":"0001193125-23-157307","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TScan Therapeutics prices $140M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$140M from 22.99M shares at $2.00/share and 47.01M pre-funded warrants at $1.9999 each.","Net proceeds estimated at $134.7M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 10.5M additional shares.","Proceeds for general corporate purposes; existing cash plus offering expected to fund operations into 2026.","Offering closed May 31 for shares and June 1 for warrants; Morgan Stanley and Wedbush lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301785,"accession_number":"0001193125-23-157286","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TScan Therapeutics appoints Gavin MacBeath as permanent CEO with increased compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gavin MacBeath, Ph.D., appointed CEO and Class I Director effective May 24, 2023; previously acting CEO since March 2023.","Base salary increased to $565,000 (from $470,000); target bonus raised to 50% of base (from 40%).","Received stock option award for 1,121,300 shares at $2.49 per share; contingent on stockholder approval of equity plan amendment.","Board also granted options for 7,403,100 shares aggregate to other recipients, subject to same amendment.","Company highlights progress in hematologic and solid tumor programs, and collaboration with Amgen for Crohn's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301784,"accession_number":"0001193125-23-146584","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.","TSC-100 in T-cell ALL patient showed T cell expansion with activation markers on Day 7 post-infusion.","Study advancing TSC-101 to Dose Level 2; RP2D and interim data expected by end of 2023.","Two control patients with MDS had incomplete donor chimerism; one in early relapse.","Phase 1 trial design includes three dose levels; second dose at DL2 and DL3 for both candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301783,"accession_number":"0001193125-23-146203","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TScan enters ATM equity offering with Wedbush, up to 2% commission","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Wedbush Securities for at-the-market issuance of common stock.","Commission of up to 2.0% of gross proceeds; Company sets sale parameters.","Shelf registration statement (333-268260) declared effective May 16, 2023; prospectus supplement filed.","No obligation to sell; either party may suspend or terminate offering on notice.","Sales may also be made to Wedbush as principal at agreed prices; customary indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301782,"accession_number":"0000950170-23-020082","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan reports Q1 net loss $22.6M; Amgen partnership adds $30M upfront, extends cash runway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.6M vs $16.2M in Q1 2022; revenue $6.8M, up from $3.0M on Novartis collaboration wind-down.","Amgen partnership for Crohn's disease targets: $30M upfront, potential milestones >$500M; cash runway extended into Q3 2024.","Phase 1 heme study: patients enrolled in all three arms; TSC-101 cleared for second dose level (two doses 40 days apart).","Cash and equivalents $95.6M at Mar 31, 2023; combined with Amgen upfront supports operations into Q3 2024.","Appointed Dr. Barbara Klencke to Board of Directors; she previously led oncology development at Sierra/GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":6803000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301781,"accession_number":"0001193125-23-139057","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.","Amgen gains exclusive global rights to develop and commercialize therapeutics from discovered targets.","Amgen holds an option to expand the collaboration to include ulcerative colitis under predefined terms.","TScan also earns tiered single-digit royalties on net sales from any products developed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301780,"accession_number":"0001193125-23-095838","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"TScan Therapeutics adds Dr. Barbara Klencke to board and promotes three to SVP","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Barbara Klencke appointed to board effective April 6, 2023; granted option for 9,146 shares vesting over 36 months.","Klencke brings 20+ years oncology drug development; was CMO of Sierra Oncology (acquired by GSK in 2022).","Shrikanta Chattopadhyay promoted to SVP, Medical, Translational Medicine; 15+ years experience.","Ann Hargraves promoted to SVP, Human Resources; previously led HR at Keurig and founded Mindset Consulting.","Ray Lockard promoted to SVP, Technical Operations and Quality; over 25 years in manufacturing and supply chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321534,"accession_number":"0001193125-23-086922","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TScan CEO David Southwell steps down; Gavin MacBeath named acting CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Southwell resigned as CEO, President, and Board member effective March 27, 2023; no disagreement with company.","Gavin MacBeath, Ph.D., appointed acting CEO effective March 28, 2023; will continue as Chief Scientific and Operating Officer.","Southwell receives 18 months salary continuation and COBRA; severance conditioned on release and compliance with restrictive covenants.","Company reaffirms cash runway into Q2 2024 with $120M cash as of Dec 31, 2022; clinical programs on track.","First patient dosed with TSC-101 on March 9, 2023; plans to provide preliminary safety/biomarker data by mid-year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321533,"accession_number":"0000950170-23-006586","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.","Q4 2022 revenue $3.1M, up from $2.9M; FY2022 revenue $13.5M (vs $10.1M in 2021).","Cash and cash equivalents $120.0M as of Dec. 31, 2022; runway into Q2 2024.","Phase 1 hematologic trial for TSC-100/101 expected to enroll all three arms by mid-2023 with preliminary safety/biomarker data.","Solid tumor INDs for T-Plex and two TCRs cleared; initial single-agent TCR data expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321532,"accession_number":"0001193125-23-012556","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TScan receives FDA clearance for three INDs in solid tumor program, including T-Plex and two MAGE-A1-targeting TCRs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared primary IND T-Plex enabling customized multiplexed TCR-T combinations based on tumor target/HLA expression.","Secondary INDs for TSC-204-A0201 and TSC-204-C0702 targeting MAGE-A1 on HLA A*02:01 and C*07:02 respectively.","MAGE-A1 overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.","TScan plans multicenter Phase 1 trial; screening protocol expected in Q2 2023, initial clinical data by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339639,"accession_number":"0000950170-22-023503","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Therapeutics reports Q3 net loss of $16.2M and cash of $137.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.2M vs $15.8M YoY; revenue $3.4M vs $2.4M YoY.","Cash and equivalents $137.3M; closed $60M debt facility with K2 HealthVentures, initial $30M drawn.","Phase 1 umbrella trial for TSC-100/101 enrolling; pre-IND meeting with FDA completed for solid tumors.","Plan IND submissions for MAGE-A1 TCRs by end 2022; HPV and PRAME INDs by H1 2023.","Virtual investor event Nov 14, 2022 to detail solid tumor clinical development plans."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":10440000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356996,"accession_number":"0001193125-22-242437","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"TScan secures up to $60M convertible debt facility with K2 HealthVentures; initial $30M tranche funds","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan and Security Agreement with K2 HealthVentures for up to $60M in convertible term loans.","First tranche of $30M fully funded at closing; second $10M and third $20M tranches subject to milestones and lender discretion.","Loans mature September 1, 2026; interest-only payments for 24 months (extendable to 36 on milestones), then amortize.","Interest rate is greater of 8.75% or Prime + 4.75%, capped at 9.90%; loan convertible at $4.785/share for first tranche.","Cash runway extended into Q2 2024; funds to support IND filings and solid tumor multiplexing trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356995,"accession_number":"0000950170-22-016253","cik":1783328,"company_name":"TScan Therapeutics, Inc.","ticker":"TCRX","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TScan Q2 net loss $15.1M; cash $125.6M funds into 2024; TSC-101 IND cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.1M vs $10.7M in prior-year quarter; revenue $4.1M (up from $2.8M) on Novartis collaboration.","Cash and equivalents $125.6M (plus $5M restricted); runway into 2024.","FDA cleared IND for TSC-101 (HA-2) for HCT relapse prevention; Phase 1 umbrella trial now enrolling.","Debora Barton, M.D., appointed Chief Medical Officer; brings cell therapy and oncology R&D experience.","Plans to file INDs for solid-tumor candidates TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":7077000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71559149.53738318,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-10T23:59:59+00:00|356995"}